This CME-certified prIME Rounds webcast centers on immunotherapy in head and neck cancer, focusing on the use of checkpoint inhibitors in squamous cell carcinoma of the head and neck.
0.75 AMA PRA Category 1 Credit™
Dec 22, 2017
Dec 22, 2018
- Why targeting immune system in SCCHN
- Use of immune checkpoint inhibitors in SCCHN in practice
- Next steps in SCCHN
Ezra Cohen, MDUniversity of California at San Diego
San Diego, California, United States
This educational activity is designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals involved in the treatment of patients with head and neck cancer.
After completion of this educational activity, participants should be able to:
- Identify rationale and current indications for use of immune checkpoint inhibitors in recurrent and metastatic HNSCC
- Explain unique patterns of response to immuno-oncology agents and management of immune-related adverse events
- Assess the potential impact of biomarkers such as human papillomavirus (HPV) status, programmed death-ligand 1 (PD-L1), mutational load, and expression profiling on response to immunotherapy
- Incorporate current and emerging immuno-oncology strategies to multidisciplinary care of head and neck cancer
This educational activity is supported by a grant from Bristol-Myers Squibb.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Cohen has disclosed that he has received consulting fees (eg, advisory boards) from AstraZeneca; Bristol-Myers Squibb; Eisai; Human Longevity, Inc.; Merck; and Pfizer. He has disclosed that he has ownership interest in Human Longevity, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
- Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.